Report By: Nandika Chand | Last Updated June 6, 2020
AstraZeneca in partnership with Serum Institute of India (SII) is set to produce a potential vaccine (AZD1222) for COVID-19. The vaccine is currently under trial on a mass scale at the University of Oxford.
An official statement by the biopharma major said in a licensing agreement with SII, they are to supply one billion doses of low-and-middle-income countries, with a commitment to provide 400 million before 2020-end. It said AstraZeneca is building supply chains in parallel across the world to support global access at no profit during the pandemic.
The company has also agreed to supply 400 million doses to the United States and the United Kingdom after reaching a licence agreement with Oxford University for its potential vaccine.
Adar Poonawalla, SII’s CEO, said the institute over the past 50-years has built significant capability in vaccine manufacturing and supply globally. He said SII is working closely with AstraZeneca to ensure fair and equitable distribution of the vaccine. Pascal Soriot, CEO AstraZeneca, said they are working tirelessly to honour its commitment to ensure a broad and equitable access to Oxford’s vaccine across the globe and at no profit.